Abstract
Despite the conventional treatments of radiation therapy and chemotherapy, the 5-year survival rates for patients with advanced-stage cervical cancers remain low. Cancer immunotherapy has emerged as an alternative, innovative therapy that may improve survival. Here, we utilize a preclinical HPV-16 E6/E7-expressing tumor model, TC-1, and employ the chemotherapeutic agent cisplatin to generate an accumulation of CD11c+ dendritic cells in tumor loci making it an ideal location for the administration of therapeutic vaccines. Following cisplatin treatment, we tested different routes of administration of a therapeutic HPV vaccinia vaccine encoding HPV-16 E7 antigen (CRT/E7-VV). We found that TC-1 tumor-bearing C57BL/6 mice treated with cisplatin and intratumoral injection of CRT/E7-VV significantly increased E7-specific CD8+ T cells in the blood and generated potent local and systemic antitumor immune responses compared to mice receiving cisplatin and CRT/E7-VV intraperitoneally or mice treated with cisplatin alone. We further extended our study using a clinical grade recombinant vaccinia vaccine encoding HPV-16/18 E6/E7 antigens (TA-HPV). We found that intratumoral injection with TA-HPV following cisplatin treatment also led to increased E7-specific CD8+ T cells in the blood as well as significantly decreased tumor size compared to intratumoral injection with wild type vaccinia virus. Our study has strong implications for future clinical translation using intratumoral injection of TA-HPV in conjunction with the current treatment strategies for patients with advanced cervical cancer.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: A Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107
Thomas GM (1999) Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. New Engl J Med 340(15):1198–1200. doi:10.1056/NEJM199904153401509
Society AC (2012) Cervical cancer: survival rates by stage. http://www.cancer.org/Cancer/CervicalCancer/DetailedGuide/cervical-cancer-survival. Accessed July 16 2012
Roden R, Wu TC (2006) How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6(10):753–763. doi:10.1038/nrc1973
Halbert CL, Demers GW, Galloway DA (1991) The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65(1):473–478
Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347(9014):1523–1527
Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC (2004) Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22(29–30):3993–4001. doi:10.1016/j.vaccine.2004.03.057
Spee P, Neefjes J (1997) TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 27(9):2441–2449. doi:10.1002/eji.1830270944
Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P (1996) Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5(2):103–114
Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez R, Roden RB, Pardoll DM, Hung CF, Wu TC (2013) Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. doi:10.1158/0008-5472.CAN-12-4241
Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, Sterling JC, Kitchener HC (2006) Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 16(3):1075–1081. doi:10.1111/j.1525-1438.2006.00598.x
Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL (2003) Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 63(18):6032–6041
Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8(12):3676–3685
Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC (1996) Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14(16):1485–1494
Chen CH, Suh KW, Ji H, Choti MA, Pardoll DM, Wu TC (2000) Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. J Hepatol 33(1):91–98
Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC (2000) Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 7(9):726–733. doi:10.1038/sj.gt.3301160
Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, Chuang CM, Lin CT, Tsai YC, He L, Monie A, Wu TC (2008) Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 14(10):3185–3192. doi:10.1158/1078-0432.CCR-08-0037
Earl PL, Moss B (1993) Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Res Human Retroviruses 9(7):589–594
Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT, Wu TC (2003) CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 10(16):1311–1320. doi:10.1038/sj.gt.3301982
Zurkova K, Babiarova K, Hainz P, Krystofova J, Kutinova L, Otahal P, Nemeckova S (2009) The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep 21(5):1335–1343
Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI (2007) Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 13(1):341–349. doi:10.1158/1078-0432.CCR-06-1838
Medicine SKCCCJH (2009) Therapeutic vaccination for patients with HPV16+ cervical intraepithelial neoplasia (CIN2/3). National Library of Medicine (US). http://clinicaltrials.gov/ct2/show/NCT00988559. Accessed July 2 2012
Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC (2009) A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15(1):361–367. doi:10.1158/1078-0432.CCR-08-1725
Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA (2009) The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother CII 58(9):1355–1362. doi:10.1007/s00262-009-0686-7
Acknowledgments
This work was supported by the Cervical Cancer SPORE, P50CA098252, the Head and Neck Cancer SPORE, P50DE019032, and 2RO1 CA114425-06 from the National Institutes of Health/National Cancer Institute.
Conflict of interest
The authors declare that no conflict of interests exist.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, S.Y., Kang, T.H., Knoff, J. et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother 62, 1175–1185 (2013). https://doi.org/10.1007/s00262-013-1421-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-013-1421-y